柳氮磺吡啶联用枫蓼肠胃康胶囊治疗溃疡性结肠炎的临床效果  

Clinical effect on Sulfasalazine combined with Fengliao Changweikang Capsules in the treatment of ulcerative colitis

作　　者：叶岚 崔颖[2] YE Lan;CUI Ying(Department of Oncology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Hubei Province,Wuhan430064,China;Department of Pharmacy,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Hubei Province,Wuhan430064,China)

机构地区：[1]武汉科技大学附属天佑医院肿瘤科,湖北武汉430064 [2]武汉科技大学附属天佑医院药学部,湖北武汉430064

出　　处：《中国当代医药》2024年第16期34-37,共4页China Modern Medicine

摘　　要：目的探讨柳氮磺吡啶联用枫蓼肠胃康胶囊治疗溃疡性结肠炎(UC)的临床效果。方法选取2022年1月至10月武汉科技大学附属天佑医院收治的76例溃疡性结肠炎患者作为研究对象,根据随机数字表法分为治疗组(38例)与对照组(38例),治疗组采用柳氮磺吡啶联用枫蓼肠胃康胶囊治疗,对照组采用柳氮磺吡啶治疗,比较两组临床疗效、血清炎症因子水平和疾病活动指数(DAI)评分。结果治疗组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗8周后,治疗组超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-10低于对照组,差异有统计学意义(P<0.05);随访4周后,治疗组的hs-CRP、TNF-α、IL-10低于对照组,差异有统计学意义(P<0.05);治疗8周后,治疗组DAI评分低于对照组,差异有统计学意义(P<0.05);随访4周后,治疗组DAI评分低于对照组,差异有统计学意义(P<0.05)。结论柳氮磺吡啶联用枫蓼肠胃康胶囊治疗UC,提高了有效率,降低了患者血清炎症因子水平和DAI评分,值得在临床推广应用。Objective To investigate the clinical effect of Sulfasalazine combined with Fengliao Changweikang Capsules in the treatment of ulcerative colitis(UC).Methods A total of 76 patients with ulcerative colitis admitted to Tianyou Hospital affiliated to Wuhan University of Science and Technology from January to October 2022 were selected as the study objects.They were divided into treatment group(38 cases)and control group(38 cases)according to random number table method.The treatment group was treated with Sulfasalazine combined with Fengliao Changweikang Capsules,and the control group was treated with Sulfasalazine.The clinical efficacy,serum inflammatory factor levels and disease activity index(DAI)score of the two groups were compared.Results The total effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).After 8 weeks of treatment,hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and interleukin(IL)-10 in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05).After 4 weeks of follow-up,hs-CRP,TNF-αand IL-10 in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05).After 8 weeks of treatment,DAI score in the treatment group was lower than that in the control group,and the difference was statistically significant(P<0.05).After 4 weeks of follow-up,DAI score in the treatment group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Sulfasalazine combined with Fengliang Changweikang Capsules in the treatment of UC can improve the effective rate,reduce the serum inflammatory factor level and DAI score of patients,which is worthy of clinical application.

关 键 词：柳氮磺吡啶 枫蓼肠胃康胶囊 溃疡性结肠炎 临床疗效 

分 类 号：R574.62[医药卫生—消化系统]